Cargando…

The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases

BACKGROUND: There is a lack of fully validated patient-reported outcome measures for progressive fibrosing interstitial lung disease (ILD). We aimed to validate the King's Brief Interstitial Lung Disease (K-BILD) questionnaire for measuring health-related quality of life (HRQoL) in these patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Birring, Surinder S., Bushnell, Donald M., Baldwin, Michael, Mueller, Heiko, Male, Natalia, Rohr, Klaus B., Inoue, Yoshikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160394/
https://www.ncbi.nlm.nih.gov/pubmed/34764181
http://dx.doi.org/10.1183/13993003.01790-2021
_version_ 1784719261419175936
author Birring, Surinder S.
Bushnell, Donald M.
Baldwin, Michael
Mueller, Heiko
Male, Natalia
Rohr, Klaus B.
Inoue, Yoshikazu
author_facet Birring, Surinder S.
Bushnell, Donald M.
Baldwin, Michael
Mueller, Heiko
Male, Natalia
Rohr, Klaus B.
Inoue, Yoshikazu
author_sort Birring, Surinder S.
collection PubMed
description BACKGROUND: There is a lack of fully validated patient-reported outcome measures for progressive fibrosing interstitial lung disease (ILD). We aimed to validate the King's Brief Interstitial Lung Disease (K-BILD) questionnaire for measuring health-related quality of life (HRQoL) in these patients. We also aimed to estimate the meaningful change threshold for interpreting stabilisation of HRQoL as a clinical end-point in progressive fibrosing ILD, where the current goal of treatment is disease stability and slowing progression. METHODS: This analysis evaluated data from 663 patients with progressive fibrosing ILD other than idiopathic pulmonary fibrosis from the INBUILD trial. Validation of the measurement properties was assessed for internal consistency, test–retest reliability, construct validity, known-groups validity and responsiveness. We calculated meaningful change thresholds for treatment response using anchor-based (within-patient) and distribution-based methods. RESULTS: K-BILD had strong internal consistency (Cronbach's α was 0.94 for total score, 0.88 for breathlessness and activities, 0.91 for psychological, and 0.79 for chest symptoms). The test–retest reliability intraclass correlation coefficient was 0.74 for K-BILD total score. K-BILD demonstrated weak correlations with forced vital capacity (FVC) percent predicted. Known-groups validity showed significant differences in K-BILD scores for patient groups with different disease severity based on use of supplemental oxygen or baseline FVC % pred (≤70% or >70%). We estimated a meaningful change threshold of ≥ –2 units for K-BILD total score for defining patients who remain stable/improved versus those with progressive deterioration. CONCLUSIONS: Our results validate K-BILD as a tool for assessing HRQoL in patients with progressive fibrosing ILD and set a meaningful change threshold of ≥ –2 units for K-BILD total score.
format Online
Article
Text
id pubmed-9160394
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-91603942022-06-05 The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases Birring, Surinder S. Bushnell, Donald M. Baldwin, Michael Mueller, Heiko Male, Natalia Rohr, Klaus B. Inoue, Yoshikazu Eur Respir J Original Research Articles BACKGROUND: There is a lack of fully validated patient-reported outcome measures for progressive fibrosing interstitial lung disease (ILD). We aimed to validate the King's Brief Interstitial Lung Disease (K-BILD) questionnaire for measuring health-related quality of life (HRQoL) in these patients. We also aimed to estimate the meaningful change threshold for interpreting stabilisation of HRQoL as a clinical end-point in progressive fibrosing ILD, where the current goal of treatment is disease stability and slowing progression. METHODS: This analysis evaluated data from 663 patients with progressive fibrosing ILD other than idiopathic pulmonary fibrosis from the INBUILD trial. Validation of the measurement properties was assessed for internal consistency, test–retest reliability, construct validity, known-groups validity and responsiveness. We calculated meaningful change thresholds for treatment response using anchor-based (within-patient) and distribution-based methods. RESULTS: K-BILD had strong internal consistency (Cronbach's α was 0.94 for total score, 0.88 for breathlessness and activities, 0.91 for psychological, and 0.79 for chest symptoms). The test–retest reliability intraclass correlation coefficient was 0.74 for K-BILD total score. K-BILD demonstrated weak correlations with forced vital capacity (FVC) percent predicted. Known-groups validity showed significant differences in K-BILD scores for patient groups with different disease severity based on use of supplemental oxygen or baseline FVC % pred (≤70% or >70%). We estimated a meaningful change threshold of ≥ –2 units for K-BILD total score for defining patients who remain stable/improved versus those with progressive deterioration. CONCLUSIONS: Our results validate K-BILD as a tool for assessing HRQoL in patients with progressive fibrosing ILD and set a meaningful change threshold of ≥ –2 units for K-BILD total score. European Respiratory Society 2022-06-02 /pmc/articles/PMC9160394/ /pubmed/34764181 http://dx.doi.org/10.1183/13993003.01790-2021 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Original Research Articles
Birring, Surinder S.
Bushnell, Donald M.
Baldwin, Michael
Mueller, Heiko
Male, Natalia
Rohr, Klaus B.
Inoue, Yoshikazu
The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
title The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
title_full The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
title_fullStr The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
title_full_unstemmed The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
title_short The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
title_sort psychometric properties of the king's brief interstitial lung disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160394/
https://www.ncbi.nlm.nih.gov/pubmed/34764181
http://dx.doi.org/10.1183/13993003.01790-2021
work_keys_str_mv AT birringsurinders thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT bushnelldonaldm thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT baldwinmichael thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT muellerheiko thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT malenatalia thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT rohrklausb thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT inoueyoshikazu thepsychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT birringsurinders psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT bushnelldonaldm psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT baldwinmichael psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT muellerheiko psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT malenatalia psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT rohrklausb psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases
AT inoueyoshikazu psychometricpropertiesofthekingsbriefinterstitiallungdiseasequestionnaireandthresholdsformeaningfultreatmentresponseinpatientswithprogressivefibrosinginterstitiallungdiseases